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Blunted kaliuresis after an acute potassium load in patients with
chronic renal failure. We evaluated renal handling and plasma potassi-
um (K) and aldosterone (PA) responses to acute oral K loading in 11
patients with tubulointerstitial renal disease (creatinine clearance 32 5
mI/mm [SE]) and 13 control subjects (creatinine clearance 123 5).
After 4 days of a 10 mEq Na, 50 mEq K diet, the subjects received 0.5
mEq KCI/kg body weight. Prior to KCI there were no differences
between the groups in plasma K or urinary K excretion (U KY). In the 4
hr following KCI, less of the load (13 4%) was excreted by patients
than control subjects (54 5%; P < 0.001). Plasma K at 3 hr post KCI,
and the amount of retained potassium translocated into the intracellular
compartment (patients 14 3; control subjects 7 2 niEq; P < 0.05)
were significantly higher in the patients than in control subjects. After
KCI, PA levels increased in both groups, and the increments in the
patients tended to exceed those of controls; patients with hypoaldoster-
onism, however, transferred less K into cells and had an even greater
impairment of renal K excretion than those with normal baseline PA.
The results indicate that the impaired response to an acute oral
potassium load in chronic renal failure is related primarily to defective
renal rather than extrarenal mechanisms.
Diminution de Ia kaliurèse apres une charge potassique aigue chez des
malades ayant une insuffisance rénale chronique. Nous avons évalud
l'excrétion rénale et les réponses du potassium (K) et de l'aldostérone
(PA) plasmatiques a une charge de K aigue orale chez 11 malades
atteints de néphropathie tubulo-interstitielle (clearance de Ia créatinine
32 5 mI/mm [SE]) et chez 13 sujets contrôles (clearance de la
créatinine 123 5). Après 4 jours d'un régime a 10 mEq de Na et 50
mEq de K, les sujets ont recu 0,5 mEq KC1/kg poids corporel. Avant
KCI, il n'y avait pas de differences entre les groupes en ce qui concerne
le K plasmatique ou l'excrétion urinaire de K (UKV). Au cours des 4
heures suivant KCI, une fraction moindre de Ia charge (13 4%) a ete
excrétée par les malades que par les sujets contrôles (54 5%; P <
0,001). Le K plasmatique, 3 heures aprés KCI, et Ia quantité du
potassium retenu, transféré vers Ic compartiment intracellulaire (ma-
lades 14 3; sujets contrOles 7 2 mEq; P < 0,05) étaient significative-
ment plus élevés chez les malades que chez les contrôles. Aprés KCI,
les niveaux de PA se sont élevés dans les deux groupes, et les
augmentations chez les malades tendaient a dépasser celles des con-
trôles; les patients avec un hypoaldostéronisme, cependant, transfer-
aient moms de K dans les cellules et avaient méme une plus grande
alteration de l'excrétion rénale de K que ceux avec une PA de base
normale. Ces résultats indiquent que l'altération de Ia réponse a une
charge aigue orale en potassium au cours de l'insuffisance rénale
chronique est primitivement reliée a des mécanismes défectueux plus
rénaux qu'extrarénaux.
The ability of patients with chronic renal failure to tolerate an
acute potassium load is impaired [1—4]. It is generally believed
that this abnormality is due primarily to an impaired extrarenal
potassium uptake [4, 5]. Nevertheless, it is reasonable to
assume that the defect may be related in part to impaired renal
potassium excretion, since in normal humans approximately
one half of an acute load is excreted in the urine over a 6-hr
period [3].
The studies [3, 4] evaluating renal potassium handling after
oral potassium administration in patients with impaired renal
function have yielded conflicting results. Gonick et al [3]
showed a blunted kaliuresis in the 6 hr following an oral
potassium load of 0.75 mEq/kg of body weight. No differences
in plasma potassium values or urinary excretion between pa-
tients with glomerular versus tubulointerstitial diseases were
noted, and peak plasma potassium levels in the patients were
not different from those of control subjects, supporting a major
role for extrarenal uptake of potassium in their patients. On the
other hand, Kahn et al [4] observed significant increases in
plasma potassium concentration in patients with chronic renal
insufficiency (in comparison to no change for controls) 4 hr after
an oral load of 25 mEq of potassium. Twenty-four-hour potassi-
um excretion was similar in both groups. Thus, the role of
extrarenal mechanisms in the maintenance of potassium ho-
meostasis after acute loads in patients with chronic renal failure
remains undefined.
In the present study we have evaluated internal and external
potassium homeostasis and plasma aklosterone responses after
an acute oral potassium load in a group of patients with
tubulointerstitial renal diseases and moderate chronic renal
insufficiency. To assess the role of aldosterone in potassium
homeostasis, we selected patients with and without underlying
hypoaldosteronism.
The experimental protocol addressed three key questions: (I)
Is there a defect in potassium excretion in chronic renal failure
that is independent of aldosterone deficiency? (2) Is there an
abnormality of cellular potassium uptake and if so, is it deter-
mined, at least in part, by aldosterone deficiency? (3) What is
the adrenal response to small, acute oral doses of potassium?
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Methods
Twenty-four subjects, 11 patients with chronic renal failure
and 13 control subjects, were evaluated. In two patients, the
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Table 1. Clinical and laboratory features of patients with chronic renal failure and control subjectsa
diagnosis of tubulointerstitial renal disease was made by renal
biopsy, three had known obstructive uropathy, and in the
remaining subjects the diagnosis was made by clinical criteria
alone. Three patients exhibited serum potassium concentra-
tions above 5.5 mEq/liter at the time of selection, 4 weeks to 6
months prior to study. Five patients manifested hyperchioremia
and two metabolic acidosis. At that time, hyperkalemic patients
received a low potassium diet or a few doses of sodium
polysterene sulfonate. Subsequently, the outpatient serum po-
tassium levels remained within the normal range by use of
moderate dietary potassium restriction. No patient was treated
with sodium polysterene sulfonate during the 4 weeks preceding
the beginning of the study. All patients were clinically stable
before the study. Patients with organic heart disease, conges-
tive heart failure, or those taking medications known to inter-
fere with potassium homeostasis were excluded. The control
group was composed of healthy volunteers (nine subjects) or
patients treated for mild dermatological conditions (four sub-
jects). The protocol was approved by the Human Studies
Subcommittee of the Miami Veterans Administration Medical
Center, Miami, Florida, and was in conformity with the princi-
ples outlined in the Declaration of Helsinki.
After admission, both patients and controls ingested a daily
diet containing 10 mEq of sodium and 50 mEq of potassium for
4 to 5 days. Body weight and blood pressure were measured
daily. A 24-hr urine collection for sodium, potassium, and
creatinine, and a blood sample for sodium, potassium, chloride,
carbon dioxide content [HCO3], creatinine, and urea nitrogen
were obtained on the last day of this special diet.
The following day, the potassium loading test was performed.
Breakfast was withheld, and each subject ambulated for 2 hr
(from 6 A.M. to 8 A.M.). At 8 AM. an indwelling polystyrene
catheter was placed in an antecubital vein, and a blood sample
for plasma renin activity (PRA), plasma aldosterone concentra-
tion (PA), creatinine, sodium, and potassium was obtained.
Thereafter, except to void, the patient assumed the recumbent
posture for the remainder of the test. At 8:05 A.M. the patient
emptied his bladder and received a water load (15 ml/kg) by
mouth over a 5-mm period. After obtaining two 30-mm baseline
urine collections and two baseline blood samples (8:30 and 9
A.M.), the patient received 0.5 mEq of potassium (as a 20%
solution of KCI in water) per kilogram of body weight dissolved
in 90 ml of water and ingested over 5 mm. Because of a prior
history of hyperkalemia three patients received a potassium
load of 0.35 mEq/kg of body weight, and a fourth patient
received only 0.25 mEq/kg of body weight. One patient and one
control subject underwent a time control study without the
potassium load.
Following the potassium load, urine collections were ob-
tained every 30 mm for 4 hr. Blood specimens were drawn
every 30 mm for the first 2 hr and hourly thereafter. Blood was
drawn without a tourniquet or fist clenching and centrifuged
immediately in a refrigerated centrifuge at 3000 rpm for 10 mm.
Aliquots for PRA and PA were then frozen immediately at
— 15°C. The blood and urine samples were analyzed for sodium
and potassium by flame photometry and for creatinine utilizing
an automated method of chemical analysis. PRA and PA were
estimated using previously reported methods [61. Statistical
analysis of the data was performed with Student's t test and,
when appropriate, using the Mann-Whitney test.
To calculate the net amount of infused potassium excreted for
any given time period, we subtracted the amount of potassium
excreted during the baseline period from the total amount
excreted during each experimental period. The amount of
administered potassium retained within the body during the 4-hr
study was calculated by subtracting the net amount of potassi-
um excreted from the amount of potassium given. The amount
of potassium that was disposed of by extrarenal mechanisms
was calculated as the difference between the amount retained in
the body and the amount sequestered in the extracellular space
(measured rise in plasma potassium multiplied by the estimated
extracellular fluid volume, assuming that the latter remained
constant at 20% of body weight).
Results
The clinical diagnoses and laboratory findings at the time of
selection for the study are shown in Table 1. The patients as a
Patients no. Clinical diagnosis
Ccr
mi/mm
SNa
-
SE SHCO S1
mEqlliter
1 CINh 31 135 4.4 24 101
2 Nephrocalcinosis 40 139 4.3 22 110
3 Chronic allograft rejection 60 141 4.1 24 106
4 Polycystic kidneys 9 139 3.9 21 103
5 CIN; hypertension 45 139 3.9 24 101
6 CIN; hypertension 45 133 6.5° 21 111
7 CIN 24 143 5.3° 23 112
8 Obstructive uropathy 38 133 4.2 25 107
9 Pyelonephritis, nephrolithiasis 38 140 4.8 17 111
10 Obstructive uropathy 15 142 5.6° 24 107
11 Obstructive uropathy 12 142 6.2° 17 115
Patients(Mean±sE) 32±5 139±1 4.9±0.3 22±1 108±1
P value
Controls (Mean SE)
<0.001
123 5
NS
141 1
NS
4.3 0.1
<0.001
27 1
NS
105 1
(N = 13)
a The following features were recorded at the time of initial evaluation several weeks to 6 months prior to study.
b CIN represents chronic interstitial nephritis.
At the beginning of the studies the serum potassium levels were 4.9, 4.2, 4.3, and 5.0 mEq/liter, respectively; see Methods for details.
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Table 2. Plasma potassium values after oral potassium loadinga
Baseline 30 mm 60 mm 90 mm 120 mm 180 mm 240 mm
Patients 4.24 0.14 4.78 0.16b 5.01 0.l9b 5.16 0.24b 4.63 0.52 4.90 0.26C 4.31 0.48
(N= 11)
P value NS NS NS NS NS <0.05 NS
Controls 4.06 0.07 4.58 0.lOb 4.70 0.08" 4.63 0.08" 4.43 0.lOb 4.22 0.07 4.10 0.08
(N = 13)
a Values are mean SE.
P < 0.001 from baseline.
P < 0.005 from baseline.
Table 3. Urinary potassium excretion after oral potassium loadinga
Cr
mi/rn in
UKV, EqImin FEK, % %K
Baseline Maximum Baseline Maximum Excreted Excreted/Cc. x 100
Patients 36 5 38 5 84 l9b 33 10 52 llb 13 4 32 10
(N = 11)
P value < 0.001 NS < 0.001 <0.05 NS < 0.001 NS
Control subjects 123 5 53 10 214 21a II 2 37 4c 54 5 45 5
(N = 13)
Abbreviations: Car, creatinine clearance (mean of five to six clearance periods); UKV, urinary potassium excretion rate; FEK, fractional
excretion of potassium; %K excreted, percent of the administered load of potassium excreted in 4 hr.
Data are mean SE.
P < 0.05 in comparison to baseline.
P < 0.001 in comparison to baseline.
group were older (58 3 [mean sEl, range, 43 to 77 years)
than the control subjects (41 4 years; range, 24 to 70; P <
0.005). There were no significant differences between the
patients and controls in plasma potassium, chloride, or sodium,
but plasma bicarbonate was lower in the patients.
Prior to potassium loading, the differences in 24-hr excretion
of sodium and potassium between patients and controls were
not statistically significant (sodium: patients, 35 10; control
subjects, 18 5; potassium: patients, 15 5; control subjects,
29 5 mEq). The day of the study baseline plasma potassium
concentrations ranged from 3.5 to 5.0 mEq/liter.
Changes in plasma potassium. The changes in plasma potas-
sium concentration following the potassium load are shown in
Table 2. Prior to the administration of potassium there were no
significant differences in plasma potassium between the patients
and control subjects. In both groups, there were significant
increases in potassium levels after administration of the load,
and the values reached a peak at 60 to 90 mm and returned to
near baseline values at 4 hr. Except for higher values at 3 hr in
the patients (patients, 4.9 0.3; control subjects 4.2 0.1
mEq/liter; P <0.05), there were no significant differences in the
hourly potassium levels between patients and control subjects.
Only patient 6 developed hyperkalemia (plasma K greater than
5.5 mEq/liter).
Both the maximal increments in plasma potassium (patients
1.0 0.1; controls 0.8 0.1) and the peak serum values
(patients 5.2 0.2; controls 4,8 0.1 mEq/liter) tended to be
higher in the patients. There were slight, albeit statistically
insignificant, differences in the absolute amount of potassium
given (patients 33 4; control subjects 39 1 mEq). Factoring
the increases in plasma potassium by the dose of potassium
administered resulted in significant differences between the
groups (patients 2.2 0.3; controls 1.5 0.1 mEq/liter/mEq/kg
of potassium administered; P < 0.05).
External potassium balance. Table 3 shows the changes in
renal potassium excretion. There was no difference in baseline
urinary potassium excretion (UKV) between patients and con-
trols, but peak UKV was almost three times higher in the
control subjects (patients 84 19; controls 214 21 Eq/min;
P < 0.001).
In the 4 hr following potassium loading, both the total amount
of potassium excreted by the patients (5 2 mEq) and the
percent of the administered dose excreted (13 4%) was much
lower than that excreted by controls (21 2 mEq and 54 5%,
respectively; P < 0.001 for both comparisons). When the
percent excretion was factored by Car, (an estimate of potassi-
um excretion per nephron) the value in the patients (32 10),
tended to remain somewhat lower than that of the controls (45
5%). If patients with hypoaldosteronism were excluded
(patients 5, 6, 8, 10, and 11, see below), however, the results in
the patients (46 8) were identical to those of controls (45
5%).
As expected, baseline fractional excretion of potassium
(FEK), calculated utilizing the mean creatinine clearance for
five to six clearance periods, was higher in patients than in
controls (33 10 vs. 11 2%; P < 0.05). Nevertheless, the
increment in FEK after the load was less in the patients and, as
a consequence, peak values did not differ between the groups.
Internal potassium balance (Table 4). The amount of admin-
istered potassium retained by the patients (28 3) was greater
than that of controls (18 2 mEq; P < 0.005). The amount of
potassium translocated into the intracellular fluid (ICF) was
also significantly higher in the patients, both in absolute terms
(patients 14 3; controls 7 2 mEq; P < 0.05) and when
expressed as a percent of the administered load (patients 42
6; controls 13 5; P < 0.005). When the amount of potassium
translocated into the ICF was expressed as a percent of the total
amount retained, the differences between patients and controls
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Table 4. Fate of administered potassiuma
Patients 33±4 5±2 13±4 28±3 86±4 14±3 42 48±6 3.8±0.6
(N = 11)
P value NS < 0.001 <0.001 < 0.005 < 0.001 < 0.05 < 0.005 NS NS
Control 39±1 21±2 54±5 18±2 46±5 7±2 13 33±8 5.0±0.7
(N = 13)
Data are mean SE.
b The values represent the amount of potassium retained in the intracellular fluid (ICF).
The values represent the increment in plasma potassium concentration.
Table 5. Plasma aldosterone responsesa
Baseline Peak APA
ngldl %zPA'
PA/PK
ngldl/mEqlliter
APA/APK
%
Patients 11 3 22 6 10 4 127 62 14 7 112 37
(N= Ii)
P value NS NS NS NS NS NS
Control 21 4 27 5d 6 2 40 16 10 3 56 19
(N = 13)
were no longer statistically significant. Factoring the incre-
ments in plasma potassium concentration by the amount of
potassium retained in the body also suggested the absence in
the patients of impaired extrarenal mechanisms (patients 3.8
0.6; controls 5.0 0.7 mEq/liter/mEq of potassium).
Renin and aldosterone responses (Table 5). After 2 hr of
ambulation PA levels tended to be lower in the patients (29 9
ngldl) than in control subjects (42 9), but these values were
not statistically different. Subsequently, the levels decreased
progressively in association with the assumption of the recum-
bent position and presumably the normal diurnal rhythm.
Immediately prior to KC1 loading, the values decreased to 11
3 ngldl in the patients and 21 4 ngldl in the control subjects.
After KCI, the peak levels of plasma aldosterone in the patients
(22 6) and in control subjects (27 5 ng/dl) were significantly
greater than the baseline values. The increments in PA and
those in PA divided by the increments in serum potassium
concentration (both in absolute and percent values) tended to
be higher in the patients than in control subjects. The hourly
changes in plasma aldosterone levels are shown in Figure 1.
There were no statistically significant differences between the
values of patients and control subjects.
Mean PRA values in response to potassium loading are
shown in Figure 1. The baseline levels were lower in the
patients (P < 0.025). Following KCI, PRA did not change
significantly in the patients but decreased progressively in the
control group to values approximately half of baseline.
In both the patient and the control subject who underwent a
time control study, plasma potassium concentration did not
increase, however, both PRA and PA declined progressively
during the 4-hr study.
Comparison between patients with normal and decreased
plasma aldosterone levels. The mean age of the patients with
reduced baseline PA levels (< 15 ng/dl) was not different from
that of patients with normal PA (low PA: 61 5; normal PA 56
5 years), and there was no correlation between age and renal
potassium excretion (r = 0.35; P > 0.2). Table 6 compares the
findings in patients with hypoaldosteronism to those of patients
with normal PA levels. As might be expected, the patients with
suppressed PA tended to have reduced renal potassium excre-
tion and greater increments in plasma potassium. Of note, they
also tended to have less potassium retained in the intracellular
fluid. The percent increase in PA in the hypoaldosteronemic
subgroup was more than twice that of the subgroup with normal
aldosterone responses. None of the differences, however,
achieved statistical significance. On the other hand, when the
increments in plasma potassium concentration were factored by
the amount of potassium retained (Fig. 2), the values in
normoaldosteronemic patients were lower than those of pa-
tients with hypoaldosteronism and control subjects (hypoaldo-
steronism 5.3 + 0.9; normoaldosteronism 2.6 + 0.3 mEqlliter/
mEq; P <0.025).
Discussion
The changes in renal potassium excretion and internal potas-
sium balance associated with chronic renal failure remain
incompletely defined. In the present study, we evaluated potas-
sium homeostasis after an acute oral potassium load in a group
of patients with tubulointerstitial renal diseases, some of whom
exhibited clinical and laboratory findings indicative of hypoal-
dosteronism. In addition to evaluating internal and external
potassium balance, we measured the acute responses of PRA
and PA to KC1 administration. The results suggest that patients
with tubulojnterstitial renal disease and chronic renal failure
exhibit a defect in renal potassium excretion. The data do not
support a previously held view [4, 5] that impaired internal
Dose Excreted Excreted Retained Retained
mEq mEq % of load mEq % of load
PK
x 100RetainedRetained ICF1' Retained ICF Retained ICF
mEq % of load % retained mEqlliterlmEq
a Data are mean SE.
b Peak-baseline PA )< 100/baseline PA.
P < 0.025; d p < 0.005 from baseline.
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per nephron was normal. The maximal increments in plasma
potassium did not differ significantly from that of control
subjects, but the values 3 hr after the load were significantly
higher in the patients. Although the defect in potassium excre-
*
tion was more severe in hypoaldosteronism, it was also noted in
patients with normal PA levels.
In chronic renal failure, the exaggerated increases in plasma
potassium levels following an acute load have been attributed to
depressed potassium uptake by cells, related perhaps to abnor-
* mal hormonal regulation (insulin, catecholamines), acidosis, or
specific transport defects [4, 5, 7]. The results of the present
study do not support such an abnormality, in fact, they indicate
that hyperkalemia was prevented by an effective translocation
of potassium into cells. Only patient 6 developed hyperkalemia
during the study due to marked abnormalities in both renal and
extrarenal mechanisms. The amount of potassium translocated
into cells was significantly greater in the patients than in the
control group. Nevertheless, since control subjects retained
r less potassium than the patients, we cannot comment definitive-ly about the significance of this finding, except to suggest that
the patient's extrarenal response appeared appropriate. Of
interest, extrarenal potassium uptake tended to be more im-
paired in the patients with hypoaldosteronism, a finding com-
patible with recent observations in the rat [8].
Because our study was performed during sodium restriction,
it is conceivable that under a normal or higher sodium intake the
lower aldosterone levels might have unmasked an abnormality
of cellular potassium uptake. The possibility that plasma cate-
cholomines were increased in our patients also cannot be
excluded. Nevertheless, since clinical or laboratory evidence of
intravascular volume depletion was not noted, this possibility
seems unlikely.
We administered the potassium load by mouth because of the
potential hazards of intravenous KC1 administration in patients
with renal failure. An important assumption made in the present
I I I I I study was that the administered dose of KC1 was absorbed
0 30 60 90 120 180 240 completely from the gastrointestinal tract. None of our subjects
developed vomiting or diarrhea prior to or during the study. To
our knowledge, there are no published data comparing potassi-
um absorption from the gut in the acute or steady state in
normal subjects and patients with chronic renal failure. One
previous study has demonstrated that in patients with a de-
crease in renal function similar to that observed in our patients,
stool potassium is low and contributes little to overall balance
[9]. Furthermore, in patient 6 who had severe impairment in
both renal and extrarenal mechanisms of potassium homeosta-
sis, the increase in extracellular fluid potassium content equaled
the amount of potassium administered indicating that the full
dose was absorbed.
Decreased urinary potassium excretion after an oral load of
potassium was observed by Gonick et al [31 in a study of
potassium excretion in patients with chronic renal failure. Peak
plasma potassium levels were not different between patients
and control subjects suggesting normal or enhanced extrarenal
uptake; the levels at the end of the study, however, were higher
in the patients. Plasma aldosterone levels were not evaluated in
that study, More recently, Kahn et al [4] evaluated potassium
homeostasis 4 hr after an oral load of 25 mEq of potassium.
Although the increments in plasma aldosterone levels in re-
sponse to potassium were normal, plasma potassium increased
Time, mm
Fig. 1. Mean SEplasma aldosterone levels and plasma renin activity
before (0 time) and for 4 hr after the administration of KCI in control
subjects (open circles, dashed lines) and patients (closed circles,
uninterrupted lines). For plasma aldosterone (top panel) the asterisks
denote changes significantly different (P < 0.025 or less) from baseline.
There were no differences between the hourly values of patients and
control subjects. For plasma renin activity the asterisks denote changes
significantly different from baseline (* P < 0.05; ** P < 0.005). The
differences between the two groups were statistically significant during
the first 2 hr after KCI (P < 0.05 or less).
potassium balance is the prepotent abnormality in these pa-
tients and suggest that the impaired acute potassium tolerance
in chronic renal failure is due primarily to a defect in renal
excretion.
Following administration of KCI, maximal rates of urine
potassium excretion, the total amount of potassium excreted,
and the percent of the administered load excreted over a 4-hr
period were lower in the patients. When the last variable was
factored for creatinine clearance, especially in patients without
hypoaldosteronism, the findings in the patients were similar to
those of control subjects, indicating that potassium excretion
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Table 6. Potassium horneostasis in patients with and without hypoaldosteronism (baseline PA < 15 ng/dl)
LPK UK Voaxt'
K
excreted K retained ICF
PK
x100Retained PAc
mEqiliter Eq/mm % of load % of load mEq/liter/mEq %
Normoaldosteronism 0.8 0.1 125 23 21 7 46 8 2.6 0.3 88 36(N = 6)
P value NS NS NS NS <0.025 NS
Hypoaldosteronism 1.2 0.3 51 11 7 2 33 9 5.3 0.9 192 134(N =5)
See Tables 3 and 4 for explanation of other symbols.
Data are mean SE.
b Peak UK V.
Peak-baseline PA x 100/baseline PA.
cc,
P
6.0
4.0
2.0
0
Fig. 2. Increments in plasma potassium concentration x 100/amount of
potassium retained as an index of extrarenal mechanisms of potassium
homeostasis in controls and patients. Bars are mean SE. The asterisk
indicates that the value in patients with normal aldosterone levels was
significantly lower than that either of patients with hypoaldosteronism
(P < 0.025) or of control subjects (P < 0.05).
significantly in the patients but not in the control subjects.
Because the rates of potassium excretion did not differ between
patients and control subjects, the authors suggested that the
cellular uptake of potassium was impaired in the patients.
Unfortunately, these authors measured only 24-hr potassium
excretion rates, and thus, they may have missed the early more
acute changes in internal or external balance.
The results of the present study in humans agree with those of
a recent report by Bourgoignie et al [10] showing blunted
kaliuresis and more severe hyperkalemia in dogs with chronic
renal failure receiving a potassium load of 50 mEq by gavage or
intravenously. The higher plasma potassium levels and aldos-
terone responses presumably worked in concert to increase
potassium excretion during the remainder of the day because
the 24-hr balance for potassium was normal.
Potassium loading has been shown to stimulate aldosterone
secretion by the adrenal gland [11, 12]. The acute response to
intravenous infusion of K has also been investigated [12]. To
our knowledge, there is no information concerning the plasma
aldosterone response to small, acute, potassium loads given by
mouth, the normal route of acquisition. The present study
confirms the data of other investigators [12] showing that
changes in plasma potassium levels within the normal range,
and as small as 0.2 to 0.3 mEq/liter, can stimulate plasma
aldosterone. The increase in PA levels was not related to
changes in the renin-angiotensin system, since PRA levels
tended to decrease or remained stable throughout the study
(Fig. 1).
The changes in PRA in response to potassium have also been
investigated by several authors [13, 15]. Unfortunately, most
studies have evaluated chronic potassium administration so that
interpretation of the results is confounded by concomitant
changes in sodium balance. In the present study, administration
of KCI was shown to be associated with an acute reduction in
PRA levels in control subjects, but not in patients with chronic
renal failure. Since both PRA and PA levels tend to decrease in
healthy subjects during the morning [161, and these values
decreased in our time control studies, we cannot conclude that
the observed decreases in PRA were related directly to KCI
administration.
In patients with hypoaldosteronism, the low PA levels are
generally believed to result from inadequate stimulation by the
renin-angiotensin system [17, 18]. It remains unclear, however,
why the high potassium levels do not exert a positive feedback
on the adrenal production of aldosterone. For example, in
anephric patients it has been shown that, in the absence of a
functioning renin-angiotensin system, potassium becomes the
main stimulus for the synthesis of aldosterone [19]. These
observations, as well as the finding of normal plasma renin
activity in some patients with hypoaldosteronism, have led to
the suggestion that the latter may be associated with a primary
adrenal defect [20]. Our results do not support this view since
the PA responses to potassium administration, when expressed
as percent changes from baseline, are normal or supranormal in
patients with hypoaldosteronism and chronic renal failure. The
absolute baseline and stimulated PA levels were lower than
those of controls, a finding that provides a partial explanation
for the observed abnormalities in internal and external potassi-
um balance.
We conclude that patients with modest chronic renal insuffi-
ciency associated with tubulointerstitial renal disease exhibit an
impaired ability to excrete an acute oral potassium load, even in
those with normal PA responses. Acute potassium homeostasis
is maintained, however, because of effective intracellular trans-
location of potassium. An obvious clinical corollary of this
formulation is that exaggerated hyperkalemia may occur in
patients given higher amounts of potassium or agents that
impair intracellular uptake of potassium or cause further impair-
ment of urinary excretion.
Control All Hypoaldo. Normoaldo-
patients steronism steronism
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